{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-092566","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.566678+00:00","generated_at":"2026-05-15T19:39:52.616526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"REGENXBIO Q4 net loss $67.1M; FDA holds on RGX-121/111; RGX-202 data expected Q2 2026","bullets":["Q4 2025 net loss $67.1M ($1.30/sh) vs $51.2M loss ($1.01/sh) in Q4 2024; FY net loss $193.9M ($3.76/sh).","Revenues for full year 2025 $170.4M (up from $83.3M in 2024) driven by Nippon Shinyaku partnership and royalty increases.","Cash and marketable securities $240.9M at Dec 31, 2025; expects operations funded into early 2027.","FDA placed clinical holds on RGX-121 and RGX-111; issued Complete Response Letter for RGX-121 BLA in Feb 2026.","RGX-202 for Duchenne: topline pivotal data expected early Q2 2026; pre-BLA meeting mid-2026. Sura-vec wet AMD data expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-092566","json":"https://secwatch.observer/filing/0001193125-26-092566.json","markdown":"https://secwatch.observer/filing/0001193125-26-092566.md","text":"https://secwatch.observer/filing/0001193125-26-092566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/0001193125-26-092566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/rgnx-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:39:52.616526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}